MyMyelomaTeam

Lenalidomide (Revlimid) has become the standard of care for maintenance therapy after stem cell transplant. It's considered well-tolerated by most patients, which is one of the main reasons it's commonly prescribed. The goal is to eliminate any remaining cancer cells and maintain remission as long as possible.

For Show Full Answer

Lenalidomide (Revlimid) has become the standard of care for maintenance therapy after stem cell transplant. It's considered well-tolerated by most patients, which is one of the main reasons it's commonly prescribed. The goal is to eliminate any remaining cancer cells and maintain remission as long as possible.

For high-risk patients specifically, doctors may recommend more intensive treatment regimens that include newer monoclonal antibodies like daratumumab (Darzalex) since outcomes tend to be different than for standard-risk patients. Current protocols suggest staying on maintenance therapy indefinitely until there is evidence of disease progression or until achieving negative minimal residual disease (MRD). Research shows the effectiveness of maintenance therapy often increases over time - in one study, lenalidomide led to negative MRD in 30% of patients after 30 months of treatment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Multiple Myeloma Maintenance Therapy: 6 Facts

Understanding the Stages of Multiple Myeloma: Q&A With Dr. Mohan